Current understanding and treatment of headache disorders: Five new things

Neurology

Volumn 76, Issue 7 SUPPL. 2, 2011, Pages

  Marmura, Michael J ^a   Silberstein, Stephen D ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; PLACEBO; TELCAGEPANT; ZOLMITRIPTAN;

ABDOMINAL PAIN; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIZZINESS; FAMILIAL HEMIPLEGIC MIGRAINE; FATIGUE; HEADACHE AND FACIAL PAIN; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOPHOBIA; PRIORITY JOURNAL; SUBARACHNOID HEMORRHAGE; THUNDERCLAP HEADACHE; TRANSFORMED MIGRAINE; VASOCONSTRICTION;

EID: 79951604084     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31820c95cc     Document Type: Article

References (40)

1. Day JW, Raskin NH. Thunderclap headache: symptom of unruptured cerebral aneurysm. Lancet 1986;2:1247-1248. (Pubitemid 17182840)
2. Ju YE, Schwedt TJ. Abrupt-onset severe headaches. Semin Neurol 2010;30:192-200.
3. Call GK, Fleming MC, Sealfon S, et al. Reversible cerebral segmental vasoconstriction. Stroke 1988;19:1159-1170.
4. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24(suppl 1):9-160.
5. Chen SP, Fuh JL, Wang SJ, et al. Magnetic resonance angiography in reversible cerebral vasoconstriction syndromes. Ann Neurol 2010;67:648-656.
6. Lu SR, Liao YC, Fuh JL, et al. Nimodipine for treatment of primary thunderclap headache. Neurology 2004;62: 1414-1416.
7. Ducros A, Boukobza M, Porcher R, et al. The clinical and radiological spectrum of reversible cerebral vasoconstric-tion syndrome: a prospective series of 67 patients. Brain 2007;130:3091-3101. (Pubitemid 350209073)
8. Chen SP, Fuh JL, Lirng JF, et al. Recurrent primary thunderclap headache and benign CNS angiopathy: spectra of the same disorder? Neurology 2006;67:2164-2169.
9. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008;71:559-566.
10. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes; a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001; 8(suppl 5):21-29. (Pubitemid 33757688)
11. Aoki KR. Evidence for antinociceptive activity of botuli-num toxin Type A in pain management. Headache 2003; 43(suppl 3):S109-S115.
12. Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L. The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 2006;122: 315-325. (Pubitemid 44250975)
13. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment: for the BOTOX Migraine Clinical Research Group. Headache 2000;40:445-450. (Pubitemid 30421875)
14. Mathew NT, Frishberg BM, Gawel M, et al. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005;45:293-307. (Pubitemid 40530193)
15. Aurora SK, Gawel M, Brandes JL, et al. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2007;47:486-499. (Pubitemid 46625251)
16. Mauskop A. The use of botulinum toxin in the treatment of headaches. Pain Physician 2004;7:377-387. (Pubitemid 39206377)
17. Aurora SK, Dodick DW, Turkel CC, et al. Onabotulinum-toxin A for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793-803.
18. Diener HC, Dodick DW, Aurora SK, et al. Onabotulinum-toxin A for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30:804-814.
19. Lebensohn JE. Photophobia: mechanism and implications. Am J Ophthalmol 1951;34:1294-1300.
20. Hattar S, Lucas RJ, Mrosovsky N, et al. Melanopsin and rod-cone photoreceptive systems account for all major accessory visual functions in mice. Nature 2003;424:76-81. (Pubitemid 36834844)
21. Noseda R, Kainz V, Jakubowski M, et al. A neural mechanism for exacerbation of headache by light: a neural mechanism for exacerbation of headache by light. Nat Neurosci 2010;13:239-245.
22. Gooley JJ, Lu J, Fischer D, Saper CB. A broad role for melanopsin in nonvisual photoreception. J Neurosci 2003; 23:7093-7106. (Pubitemid 36975874)
23. Buzzi MG, Dimitriadou V, Theoharides TC, Moskowitz MA. 5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigem-inal stimulation. Brain Res 1992;583:137-149.
24. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-187. (Pubitemid 20244522)
25. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33:48-56. (Pubitemid 23009909)
26. Recober A, Kaiser EA, Kuburas A, Russo AF. Induction of multiple photophobic behaviors in a transgenic mouse sensitized to CGRP. Neuropharmacology 2010; 58:156-165.
27. Burstein R, Levy D, Jakubowski M. Effects of sensitization of trigeminovascular neurons to triptan therapy during migraine. Rev Neurol 2005;161:658-660. (Pubitemid 40933999)
28. Cady R, Martin V, Mauskop A, et al. Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies. Cephalalgia 2007;27: 1055-1060. (Pubitemid 47296031)
29. Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache 2004;44:414-425. (Pubitemid 38685549)
30. Diener HC, Katsarava Z. Medication overuse headache. Curr Med Res Opin 2001;17(suppl 1):S17-S21.
31. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (Telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008; 372:2115-2123.
32. Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of Telcagepant for the acute treatment of migraine. Neurology 2009;73:970-977.
33. Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996;87:543-552. (Pubitemid 26374327)
34. Vanmolkot KR, Kors EE, Turk U, et al. Two de novo mutations in the Na,K-ATPase gene ATP1A2 associated with pure familial hemiplegic migraine. Eur J Hum Genet 2006;14:555-560.
35. Dichgans M, Freilinger T, Eckstein G, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 2005;366:371-377. (Pubitemid 41073954)
36. Tikka-Kleemola P, Artto V, Vepsalainen S, et al. A visual migraine aura locus maps to 9q21-q22. Neurology 2010; 74:1171-1177.
37. Troglio F, Echart C, Gobbi A, et al. The Rai (Shc C) adaptor protein regulates the neuronal stress response and protects against cerebral ischemia. Proc Natl Acad Sci USA 2004;101:15476-15481. (Pubitemid 39441566)
38. Lafreniere RG, Cader MZ, Poulin JF, et al. A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura. Nat Med 2010;16: 1157-1160.
39. Anttila V, Stefansson H, Kallela M, et al. The International Headache Genetics Consortium: genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat Genet 2010;42:869-873.
40. Boycott HE, Wilkinson JA, Boyle JP, et al. Differential involvement of TNF alpha in hypoxic suppression of astrocyte glutamate transporters. Glia 2008;56:998-1004.